Abstract
This review highlights progress made in the development of vaccines aimed at the stages of malaria parasites found in mosquitoes that block the transmission of malaria within a community. Substantial progress has been made on the production and characterization of the leading candidates P25 and P28 from Plasmodium falciparum and P. vivax. Immunogenicity data have been obtained for P25 in humans that showed significant transmission blocking activity and further advances in formulation should boost this activity. The completion of the malaria genome and ongoing proteomics identified further candidate antigens now entering development. Recent advances increase confidence that a mosquito stage transmission blocking malaria vaccine will be feasible.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
